MarketPeel
Insider Trading Intelligence
MC

Mitchell Chan

AVTX
DIRECTOR · AVALO THERAPEUTICS, INC. · CIK 0001789335
FILING MIX · LIFETIME76%/24%
BUYS
13
SELLS
4
TOTAL VALUE
$116.2K
COMPANIES
2
ACTIVE SINCE
Dec 2021
HOLDINGS NOW
42,816
AVG SELL PX
$14.41
TRADE KIND
SHOWING 17 / 17
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 5 pending
Forward-return performance of every backtestable P/S trade by Mitchell Chan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%-8.99%+1.16%-10.14%-10.14%
14d1+100.00%-25.93%
30d1+100.00%-35.99%+3.18%-39.17%-39.17%
60d1(1 pending)
90d1(1 pending)
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AVTX · 3,166 shares · as of May 6, 2026
020,00040,00060,00080,00020222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 13 buys / 4 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AVTX
AVALO THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,167$22.88$72.5K3,166May 6, 2026May 7, 2026View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
3,1663,167Mar 28, 2026Mar 31, 2026View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
3,1666,333Mar 28, 2026Mar 31, 2026View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
73,749127,717Jan 6, 2026Jan 8, 2026View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
39,65039,650Jan 6, 2026Jan 8, 2026View →
RGNX
REGENXBIO INC.
SALE
Chief Financial Officer
4,901$8.93$43.8K53,968Sep 1, 2025Sep 3, 2025View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,10020,100Jun 17, 2025Jun 18, 2025View →
AVTX
AVALO THERAPEUTICS, INC.
SALE
3,1676,333Mar 28, 2025Apr 1, 2025View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASE
3,1673,167Mar 28, 2025Apr 1, 2025View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
62,54762,547Jan 2, 2025Jan 6, 2025View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
289,362289,362Sep 16, 2024Sep 18, 2024View →
RGNX
REGENXBIO INC.
PURCHASEGRANT
Stock grant
58,86958,869Sep 16, 2024Sep 18, 2024View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
24,60024,600Aug 13, 2024Aug 14, 2024View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,5009,500Aug 13, 2024Aug 14, 2024View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,3343,334Dec 20, 2023Dec 21, 2023View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,00040,000Jun 14, 2022Jun 15, 2022View →
AVTX
AVALO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
80,00080,000Dec 1, 2021Dec 3, 2021View →
Other insiders · AVTX
Loading peer insiders…
About this filer
CIK 0001789335
ROLE
Director
PRIMARY
AVTX
COMPANIES
2
ACTIVE SINCE
Dec 2021
MARKETPEEL · /INSIDER/0001789335DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback